Gani Adiwinata, Gribok Andrei V, Lu Yinghui, Ward W Kenneth, Vigersky Robert A, Reifman Jaques
Bioinformatics Cell, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, MD 21702, USA.
IEEE Trans Inf Technol Biomed. 2010 Jan;14(1):157-65. doi: 10.1109/TITB.2009.2034141. Epub 2009 Oct 23.
This paper tests the hypothesis that a "universal," data-driven model can be developed based on glucose data from one diabetic subject, and subsequently applied to predict subcutaneous glucose concentrations of other subjects, even of those with different types of diabetes. We employed three separate studies, each utilizing a different continuous glucose monitoring (CGM) device, to verify the model's universality. Two out of the three studies involved subjects with type 1 diabetes and the other one with type 2 diabetes. We first filtered the subcutaneous glucose concentration data by imposing constraints on their rate of change. Then, using the filtered data, we developed data-driven autoregressive models of order 30, and used them to make short-term, 30-min-ahead glucose-concentration predictions. We used same-subject model predictions as a reference for comparisons against cross-subject and cross-study model predictions, which were evaluated using the root-mean-squared error (RMSE) and Clarke error grid analysis (EGA). We found that, for each studied subject, the average cross-subject and cross-study RMSEs of the predictions were small and indistinguishable from those obtained with the same-subject models. These observations were corroborated by EGA, where better than 99.0% of the paired sensor-predicted glucose concentrations lay in the clinically acceptable zone A. In addition, the predictive capability of the models was found not to be affected by diabetes type, subject age, CGM device, and interindividual differences. We conclude that it is feasible to develop universal glucose models that allow for clinical use of predictive algorithms and CGM devices for proactive therapy of diabetic patients.
可以基于一名糖尿病患者的葡萄糖数据开发一种“通用的”、数据驱动的模型,随后将其应用于预测其他患者(甚至是患有不同类型糖尿病的患者)的皮下葡萄糖浓度。我们采用了三项独立研究,每项研究使用不同的连续血糖监测(CGM)设备,以验证该模型的通用性。三项研究中有两项涉及1型糖尿病患者,另一项涉及2型糖尿病患者。我们首先通过对皮下葡萄糖浓度数据的变化率施加约束来对其进行过滤。然后,使用过滤后的数据,我们开发了30阶的数据驱动自回归模型,并使用它们进行提前30分钟的短期血糖浓度预测。我们将同一患者的模型预测作为参考,与跨患者和跨研究的模型预测进行比较,后者使用均方根误差(RMSE)和克拉克误差网格分析(EGA)进行评估。我们发现,对于每个研究对象,预测的平均跨患者和跨研究RMSE很小,与同一患者模型获得的RMSE没有区别。EGA证实了这些观察结果,其中超过99.0%的传感器预测血糖浓度对落在临床可接受的A区。此外,发现模型的预测能力不受糖尿病类型、患者年龄、CGM设备和个体差异的影响。我们得出结论,开发通用的葡萄糖模型是可行的,该模型允许在临床中使用预测算法和CGM设备对糖尿病患者进行积极治疗。